{
    "clinical_study": {
        "@rank": "117649", 
        "arm_group": [
            {
                "arm_group_label": "Adolescents (12-17yrs)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Children (6-11 yrs)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to determine the rate and extent of absorption of one or\n      more modified release formulations of amphetamine (HLD100) in both adolescents and children\n      with ADHD."
        }, 
        "brief_title": "A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and D)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Attention-Deficit Hyperactivity Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria\n\n          -  Male and female adolescents (12-17 years; Stage 1) and children (6-11 years; Stage\n             2).\n\n          -  Diagnosis of ADHD and confirmed on Kiddie-Schedule for Affective Disorders and\n             Schizophrenia (K-SADS).\n\n          -  ADHD symptoms controlled on a stable dose of Vyvanse, Adderall XR and or Dexedrine.\n\n          -  Provision of informed consent (from parent[s] or legal representative[s]) and assent\n             (from subject) for patients.\n\n        Main Exclusion Criteria\n\n          -  Comorbid psychiatric diagnosis (e.g., psychosis, bipolar disorder).\n\n          -  History of seizures or current diagnosis or family history of Tourette's disorder.\n\n          -  Use of prescription drugs (except Vyvanse, Dexedrine or Adderall XR) the 14 days and\n             over-the-counter drugs (except birth control) the 30 days before the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886469", 
            "org_study_id": "HLD100-102", 
            "secondary_id": "HLD100-102 (Control # 163513)"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Adolescents (12-17yrs)", 
                    "Children (6-11 yrs)"
                ], 
                "description": "d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)", 
                "intervention_name": "HLD100-B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Adolescents (12-17yrs)", 
                    "Children (6-11 yrs)"
                ], 
                "description": "d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.", 
                "intervention_name": "HLD100-C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Adolescents (12-17yrs)", 
                    "Children (6-11 yrs)"
                ], 
                "description": "d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.", 
                "intervention_name": "HLD100-E", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amphetamine", 
                "Dextroamphetamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Saskatoon", 
                    "country": "Canada", 
                    "state": "Saskatchewan", 
                    "zip": "S7N 0W8"
                }, 
                "name": "Saskatoon Centre for Patient-Oriented Research, Royal University Hospital, Room 5681, C Wing"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Two-Stage, Open-Label, Single-Treatment, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of up to Three Separate HLD100 Modified Release Formulations of Dextroamphetamine Sulfate in Adolescent (Stage 1) and Pediatric (Stage 2) Patients With Attention-Deficit Hyperactivity Disorder.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Rate and Extent of absorption of d-amphetamine (AUC0-tz, AUC0-\u221e, Cmax, Tmax, absorption lag time, \u03bbz, and t1/2elim)", 
            "safety_issue": "No", 
            "time_frame": "48hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886469"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety (AEs, ECG, laboratory parameters, physical examinations)", 
            "safety_issue": "Yes", 
            "time_frame": "48 hours"
        }, 
        "source": "Ironshore Pharmaceuticals and Development, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ironshore Pharmaceuticals and Development, Inc", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}